Surya Nath Pandey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Surya Nath Pandey has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chandana Maji
Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India
1 shared publication - Gaurav Gupta
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates
1 shared publication - Haider Ali
Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, India
1 shared publication - Kavita Goyal
Sharda University, Greater Noida, India
1 shared publication - Manjunath Mirle Rekha
Department of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, India
1 shared publication Mohammad Afzal
Department of Pharmaceutical Sciences, Pharmacy Program, Batterjee Medical College, Jeddah, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Ubiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract
- 31 January 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessUbiquitination and deubiquitination as critical modulators of NSCLC tumorigenesis and drug resistance
Ubiquitination and deubiquitination are biological mechanisms that including the addition and removal ubiquitin molecules from proteins, which are associated with NSCLC. NSCLC is the most common kind of lung cancer, and treatment resistance and cancer development are linked to these alterations. Ubiquitination incorporates proteins by a particular enzyme class, and deubiquitination removes ubiquitins. In NSCLC, this modification is detrimental to cellular function and affects tumorigenesis, apoptosis, and signaling pathways. Conversely, deubiquitination refers to the process through which the ubiquitins are removed from the proteins so that they can perform their functions properly. These processes can be considered therapeutic in some sense, as regulating both can result in an effective therapy for NSCLC. Many studies have been carried out to find potential areas where further drug research could be focused. This study examines the functions of ubiquitination and deubiquitination in NSCLC pathogenesis and resistance, focusing on their mechanisms, consequences, and therapeutic possibilities. Graphical Abstract